: FDA declines to authorize fluvoxamine as a COVID-19 treatment #FinanceUSA #StockMarketNEWS The Food and Drug Administration said Monday that it won't authorize fluvoxamine, a generic treatment for
@stockMarketNEWS Tue 17 May, 2022
FDA declines to authorize fluvoxamine as a COVID-19 treatment #FinanceUSA #StockMarketNEWS
The Food and Drug Administration said Monday that it won't authorize fluvoxamine, a generic treatment for obsessive-compulsive disorder, as a COVID-19 therapy. "The FDA has determined that the data are insufficient to conclude that fluvoxamine may be effective in the treatment of nonhospitalized patients with COVID-19 to prevent progression to severe disease and/or hospitalization," the regulator said, citing the need to look at the totality of scientific data. A group of physicians led by the University of Minnesota's Dr. David Boulware in late 2021 formally requested that the FDA authorize fluvoxamine as a COVID-19 treatment. "I'm disappointed that FDA holds generics to different standards as big pharma, in this case using different definition of endpoints of what is a [COVID-19-related] 'hospitalization,'" Boulware tweeted Monday.
Munafa USA Munafa India Munafa NSE
More posts by @stockMarketNEWS
: S&P 500, Nasdaq Composite finish lower Monday after earlier stock gains fizzle #FinanceUSA #StockMarketNEWS U.S. stocks closed mixed Monday, with equities losing steam in the final 15 minutes of trade.
@stockMarketNEWS Tue 17 May, 2022
: Six Flags revenue jumps above expectations, boosted by increased spending by guests #FinanceUSA #StockMarketNEWS Six Flags Entertainment Corp. reported Thursday a narrower-than-expected first-quarter
@stockMarketNEWS Fri 13 May, 2022
0 Comments
Sorted by latest first Latest Oldest Best